# Metabolic Responses of Dapagliflozin vs Sitagliptin in T2DM Patients Inadequately Controlled With Insulin Therapy

> **NCT03959501** · PHASE4 · COMPLETED · sponsor: **The University of Hong Kong** · enrollment: 60 (actual)

## Conditions studied

- Type 2 Diabetes
- Ketonemia

## Interventions

- **DRUG:** Dapagliflozin 10 mg
- **DRUG:** Sitagliptin 100mg

## Key facts

- **NCT ID:** NCT03959501
- **Lead sponsor:** The University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-16
- **Primary completion:** 2020-10-16
- **Final completion:** 2020-10-16
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2021-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03959501

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03959501, "Metabolic Responses of Dapagliflozin vs Sitagliptin in T2DM Patients Inadequately Controlled With Insulin Therapy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03959501. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*